Flag of the European Union EU Clinical Trials Register Help

Clinical trials for - Crohn’s Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28,501 result(s) found for: - Crohn’s Disease. Displaying page 564 of 1,426.
    «« First « Previous 560  561  562  563  564  565  566  567  568  Next» Last»»
    EudraCT Number: 2020-001313-20 Sponsor Protocol Number: WR42221 Start Date*: 2021-10-21
    Sponsor Name:F. Hoffman-La Roche Ltd
    Full Title: A PHASE IIIb, GLOBAL, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR−MASKED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB I...
    Medical condition: Neovascular age-related macular degeneration (nAMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003215-19 Sponsor Protocol Number: 270-301 Start Date*: 2017-11-25
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Res...
    Medical condition: Haemophilia A
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) FR (Completed) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004483-22 Sponsor Protocol Number: D967LC00001 Start Date*: 2020-09-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtec...
    Medical condition: Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000239-34 Sponsor Protocol Number: PONTIACII Start Date*: 2015-12-30
    Sponsor Name:Medizinische Universität Wien
    Full Title: NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial
    Medical condition: The purpose of this study is to evaluate the effect of high dose Renin-Angiotensin System (RAS)-antagonists and beta-blocker treatment for the primary prevention of cardiac events in a population o...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001929-32 Sponsor Protocol Number: 2014/2126 Start Date*: 2014-08-25
    Sponsor Name:Gustave Roussy
    Full Title: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
    Medical condition: Diffuse Intrinsic Pontine Glioma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2017-000397-10 Sponsor Protocol Number: DSC/14/2357/51 Start Date*: 2017-07-31
    Sponsor Name:ITALFARMACO S.p.A.
    Full Title: Studio in aperto a lungo termine volto a valutare la sicurezza, la tollerabilità e l'efficacia di GIVINOSTAT in pazienti affetti da distrofia muscolare di Duchenne che sono stati precedentemente tr...
    Medical condition: Distrofia Muscolare di Duchenne (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011613-24 Sponsor Protocol Number: HOVON102AML/SAKK30/09 Start Date*: 2010-01-25
    Sponsor Name:HOVON Foundation
    Full Title: Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously ...
    Medical condition: - a cytopathologically confirmed diagnosis of AML according WHO classification (excluding acute promyelocytic leukaemia) or - a diagnosis of refractory anemia with excess of blasts (RAEB) and ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054592 Refractory anemia with an excess of blasts LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038270 Refractory anaemia with an excess of blasts PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066353 Treatment related acute myeloid leukemia LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002380-24 Sponsor Protocol Number: 1200.125 Start Date*: 2012-02-22
    Sponsor Name:Boehringer Ingelheim España, S.A
    Full Title: LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-...
    Medical condition: Squamous cell carcinoma of the lung requiring second-line therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025126 Lung squamous cell carcinoma stage unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PT (Completed) GR (Completed) DK (Completed) HU (Completed) IE (Completed) GB (Completed) AT (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023963-16 Sponsor Protocol Number: 1014802/202 Start Date*: 2012-01-05
    Sponsor Name:Convergence Pharmaceuticals Ltd
    Full Title: A Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients with Trigeminal Neuragia
    Medical condition: Trigeminal neuralgia
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10029227 Neuralgia trigeminal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed) IT (Completed) ES (Completed) LV (Completed) LT (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001972-36 Sponsor Protocol Number: CSOM230C2305 Start Date*: 2007-11-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, blinded study to assess the safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly.
    Medical condition: Acromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular diseas...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) BE (Completed) GB (Completed) GR (Completed) IT (Completed) ES (Completed) NL (Completed) DK (Completed) SE (Completed) HU (Completed) PL (Completed) PT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015504-25 Sponsor Protocol Number: GAO4753g Start Date*: 2010-06-04
    Sponsor Name:GENENTECH, Inc
    Full Title: An Open Label, Multicenter, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + RO5072759 (GA101) in patients with Rituximab-refractory, ...
    Medical condition: CD20+, indolent NHL
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) AT (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) ES (Completed) SE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-006072-11 Sponsor Protocol Number: CASA404A2301 Start Date*: 2008-05-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (sta...
    Medical condition: This phase III trials is conducted world-wide in order to demonstrate safety and efficacy of ASA404 in combination with a paclitaxel-carboplatin chemotherapy in the treatment of patients with stage...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066490 Progression of non small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Completed) CZ (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) HU (Completed) FR (Completed) SE (Prematurely Ended) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-016196-29 Sponsor Protocol Number: M11-327 Start Date*: 2010-07-19
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate-, Posterior-, or Pan-uveitis
    Medical condition: Non-infectious Intermediate-, Posterior-, or Pan-uveitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022557 Intermediate uveitis LLT
    12.1 10033687 Panuveitis LLT
    12.1 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) PT (Completed) GB (Completed) DE (Completed) DK (Completed) AT (Completed) IT (Completed) CZ (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-000158-61 Sponsor Protocol Number: CXA30009 Start Date*: 2005-07-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10039073 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) AT (Completed) HU (Completed) ES (Completed) IE (Completed) EE (Prematurely Ended) LV (Completed) CZ (Completed) IT (Completed) LT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000387-39 Sponsor Protocol Number: BO18255 Start Date*: 2005-07-04
    Sponsor Name:Hoffmann-La Roche Ltd/Inc/AG/Roche Global Development
    Full Title: An open-label randomized multicentre phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2 positi...
    Medical condition: Advanced gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    7.1 10017767 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) GB (Completed) DE (Completed) DK (Completed) BE (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014296-40 Sponsor Protocol Number: A3921032 Start Date*: 2009-11-12
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IE (Completed) BE (Completed) FR (Completed) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001152-12 Sponsor Protocol Number: EFC6260 Start Date*: 2007-10-15
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 1...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FI (Completed) FR (Completed) AT (Completed) HU (Completed) DK (Completed) EE (Completed) SK (Completed) BG (Completed) LT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001586-15 Sponsor Protocol Number: 5065 Start Date*: 2007-10-16
    Sponsor Name:University of Southampton
    Full Title: GRACE (Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe).Workpackage 10: Antibiotic Trial One
    Medical condition: Lower Respiratory Tract Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008477 Chest infection LLT
    9.1 10024968 Lower respiratory tract infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) BE (Completed) SE (Completed) ES (Completed) IT (Completed) DE (Completed) FR (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-003772-35 Sponsor Protocol Number: AURA-6202-006 Start Date*: 2007-09-09
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers.
    Medical condition: Advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung, non small cell lung and squamous non small cell lung cancers.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) FR (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022313-25 Sponsor Protocol Number: CL-503012 Start Date*: 2011-01-17
    Sponsor Name:A.T. Development Switzerland SARL
    Full Title: International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA™ in Preventing Renal Function Decline in Patients With AA Amyloidosis
    Medical condition: Renal Function Decline in Patients With AA Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004870 10002024 Amyloidosis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SE (Completed) GB (Completed) NL (Completed) CZ (Completed) FI (Completed) DE (Completed) ES (Completed) BE (Completed) PL (Completed) IT (Completed) BG (Completed) PT (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 560  561  562  563  564  565  566  567  568  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 26 07:55:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA